Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 1.73B |
| Revenue (ttm) | 5.74B |
| Net Income (ttm) | -3.62B |
| Shares Out | 1.12B |
| EPS (ttm) | -4.18 |
| PE Ratio | n/a |
| Forward PE | 11.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,487,100 |
| Average Volume | 9,452,645 |
| Open | 1.520 |
| Previous Close | 1.550 |
| Day's Range | 1.500 - 1.610 |
| 52-Week Range | 1.090 - 6.500 |
| Beta | 1.11 |
| RSI | 47.13 |
| Earnings Date | May 7, 2026 |
About BVMF:ONCO3
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, chemotherapy, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stoma... [Read more]
Financial Performance
In 2025, BVMF:ONCO3's revenue was 5.74 billion, a decrease of -7.83% compared to the previous year's 6.23 billion. Losses were -3.62 billion, 460.8% more than in 2024.
Financial StatementsNews
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q4 2025
Leadership transition and strategic refocus led to a 7% revenue decline and over 30% drop in EBITDA, driven by major client losses and liquidity events. Debt restructuring and asset sales are underway, with ongoing creditor negotiations.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q3 2025
Significant restructuring and a BRL 1.4 billion capital increase enabled a return to core oncology, improved margins, and reduced leverage. Asset sales and operational efficiencies drove sequential EBITDA and cash flow gains, with guidance for double-digit growth and lower CapEx.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q2 2025
Q2 2025 saw stable gross revenue and a 38.3% sequential rise in adjusted EBITDA, but net loss and negative cash flow persisted due to client discontinuations and high financial expenses. Revenue is expected to decelerate in Q3 as major contracts end, but new client growth and margin recovery are anticipated.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q1 2025
Revenue and margins were pressured by a strategic reduction in exposure to certain payers, resulting in slower growth and margin compression, but cash flow and working capital improved. Cost-saving initiatives and new partnerships are expected to support future recovery and margin stabilization.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q4 2024
2024 was a year of transition, with improved capital structure, reduced net debt, and a focus on cash generation. Margins were impacted by restructuring and sector challenges, but new partnerships and operational efficiencies are expected to drive margin recovery and growth in 2025.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q3 2024
Q3 2024 saw a major turnaround to positive free cash flow, driven by improved receivables, cost discipline, and restructuring. Revenue and procedures grew organically, while leverage and working capital improved. Focus remains on cash generation and efficiency.
Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q2 2024
Double-digit revenue and EBITDA growth in Q2 2024, with improved margins, reduced leverage, and strong cash flow. Growth was driven by higher patient volume and strategic partnerships, while sector challenges and one-off regional impacts were managed effectively.